Terns Pharmaceuticals, Inc. announced that new preclinical data from a transgenic mouse model evaluating TERN-601, the Company’s novel oral GLP-1R agonist, were highlighted in a poster presentation at the American Diabetes Association’s 83rd Annual Scientific Sessions, which took place from June 23-26, 2023 in San Diego. Humanized GLP-1R (hGLP-1R) mice were used to assess the in vivo pharmacodynamics of TERN-601. In an intraperitoneal glucose tolerance test, all TERN-601 doses reduced blood glucose in hGLP-1R mice during glucose challenge.

Food intake was also recorded for 24 hours in fasted mice treated with TERN-601, with food available 15 minutes post dose. TERN-601 reduced food-intake in fasted hGLPR-1R mice. Acetaminophen (APAP) plasma levels were reduced in fasted hGLP-1R mice administered TERN-601 four hours prior to oral ingestion of APAP-glucose solution, indicating slowed gastric emptying.